Implementation of eHealth Delivery Alternatives for Cancer Genetic Testing for Hereditary Cancer (eREACH3)

NCT07471958 | Recruiting

• 2 other identifiers: UPCC 12025IRB#858825
• Study Type: observational
• Target: 360
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of the study is to understand patient interest in telehealth and digital tools for pre-test genetic education and/or disclosure of genetic test results. Participants will receive telehealth genetic counseling in the home and may be offered various digital tools to help with the counseling and testing process. These are optional and participants can still speak with a genetic counselor if they wish.

Conditions

Cancer

Outcome Measures

Primary Outcomes (3)

• Uptake of Visit 1

  Participant completion of Visit 1 (yes/no)

  Through 6 months

• Uptake of Digital Visit 1

  Participant completion of digital intervention as an alternative for Visit 1 (yes/no)

  Through 6 months

• Uptake of genetic testing

  Participant completion of genetic testing and received results/Visit 2 (yes/no)

  Through 6 months

Secondary Outcomes (6)

• The KnowGene Scale

  Through study completion, an average of 6 months

• Test result recall

  Through study completion, an average of 6 months

• Impact of Events Scale (IES)

  Through study completion, an average of 6 months

• Satisfaction with genetic services

  Through study completion, an average of 6 months

• Multi-dimensional Impact of Cancer Risk Assessment Questionnaire (MICRA)

  Through study completion, an average of 6 months

Study Arms (1)

Visit 1

All participants will be offered remote telehealth Visit 1 services by telephone or real-time videoconference or by a chatbot (patient choice).

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Individuals with personal or family history of cancer.

You may qualify if:

• years of age or older
• Speak and understand English
• Meet current National Comprehensive Cancer Network (NCCN) or other national guidelines for germline genetic testing or are interested in genetic counseling based on personal or family history of cancer. Patients with prior genetic testing are eligible if they meet criteria for updated testing, or if post-test genetic counseling services are requested.

You may not qualify if:

• Communication difficulties such as:
• Uncorrected or uncompensated hearing and/or vision impairment. Patients who can successfully use clinical assistance devices are not excluded.
• Uncorrected or uncompensated speech defects. Patients who can successfully use clinical assistance devices are not excluded.
• Uncontrolled psychiatric/mental condition or severe physical, neurological or cognitive deficits rendering individual unable to understand study goals and tasks

Sponsors & Collaborators

• Abramson Cancer Center at Penn Medicine: lead
• Fox Chase Cancer Center: collaborator

Study Sites (1)

Abramson Cancer Center at the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

RECRUITING

MeSH Terms

Conditions

Neoplasms

Study Officials

• Angela Bradbury, MD

  University of Pennsylvania

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Angela Bradbury, MD

CONTACT

215-615-3341; angela.bradbury@pennmedicine.upenn.edu

Kelsey Karpink

CONTACT

215-662-3531; kelsey.karpink@pennmedicine.upenn.edu

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 13, 2025
• First Posted: March 13, 2026
• Study Start: September 2, 2025
• Primary Completion (Estimated): March 1, 2029
• Study Completion (Estimated): March 1, 2029
• Last Updated: March 13, 2026

Record last verified: 2026-03

Locations

US (1)